Immunome, Inc.IMNMNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank57
3Y CAGR-18.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-18.9%/yr
Annual compound
Percentile
P57
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 34.57% |
| 2024 | 461.06% |
| 2023 | -0.79% |
| 2022 | 64.93% |
| 2021 | 109.63% |
| 2020 | -23.71% |
| 2019 | 28.30% |
| 2018 | 0.00% |